Dr. Roach: Man with very low kidney function chooses to avoid dialysis

Surprisingly, his heart health, cholesterol and blood pressure are always great when tested.

Dear Doctor: How long can someone with very low kidney function avoid dialysis?

People with progressive kidney failure may suffer from medical emergencies such as critically high potassium levels or severe ...
AllAfrica on MSN

Nigeria Struggles With Essential Care for Bleeding Disorders As Global Medicine Moves to Gene Therapy

Haemophilia prevalence is estimated at one in 10,000 live births, affecting up to 465,000 individuals globally, according to data from the World Federation of Haemophilia.Inside the living room of a ...
Le Lézard

Genentech's Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the pivotal Phase III study (FENhance 1) of fenebrutinib in RMS met its primary endpoint, showing clinically ...
Mid-Day

Battling Cancer Early: Bengaluru's Call for Proactive Health

Early cancer screening in Bengaluru helps detect breast, ovarian and prostate cancers sooner.

Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates

PYRUKYND is the only medicine approved in the UAE for adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia NewBridge Pharmaceuticals, a regional specialty company ...

[Ad hoc announcement pursuant to Art. 53 LR] Roche's fenebrutinib confirms its potential as first and only BTK inhibitor for relapsing and primary progressive MS in …

FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to ...